SCHEMBL5398657

SCHEMBL5398657

Fc1ccc(-c2nn3ccccc3c2-c2ccnc(NC3CC3)n2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 9/20 0.56
MAPK8 P45983 8/20 0.56
CSNK1D P48730 1/20 0.54
GSK3B P49841 5/20 0.53
MAPK14 Q16539 2/20 0.53
EGFR P00533 1/20 0.53
RAF1 P04049 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
ADORA2A P29274 1/20 0.53
ADORA2B P29275 1/20 0.53
ADORA1 P30542 1/20 0.53
CDK4 P11802 3/20 0.52
MAPK13 O15264 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
MAPK10 P53779 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE10A Q9Y233 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22106050 0.89 MAPK9 (0.60) MAPK9MAPK8CSNK1DGSK3BMAPK14
SCHEMBL5209145 0.89 MAPK9 (0.48) MAPK9MAPK8CSNK1DGSK3BCDK4
SCHEMBL5214203 0.85 MAPK9 (0.48) MAPK9MAPK8CSNK1DCDK4MAPK10
SCHEMBL5385928 0.84 MAPK14 (0.54) MAPK9MAPK8CSNK1DGSK3BMAPK14
SCHEMBL5209413 0.84 MAPK9 (0.55) MAPK9MAPK8GSK3BCDK4MAPK10
SCHEMBL5214451 0.83 CSNK1D (0.51) MAPK9MAPK8CSNK1DGSK3BMAPK14
SCHEMBL5761865 0.82 MAPK9 (0.62) MAPK9MAPK8CSNK1DGSK3BMAPK14
SCHEMBL5726060 0.82 CSNK1D (0.51) MAPK9MAPK8CSNK1DGSK3BMAPK14
SCHEMBL5388522 0.82 MAPK14 (0.56) MAPK9MAPK8CSNK1DGSK3BMAPK14
SCHEMBL5214973 0.82 CSNK1D (0.51) MAPK9MAPK8CSNK1DGSK3BMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166597-B2 Fused pyrazole derivatives being protein kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
US-7166597-B2 Fused pyrazole derivatives being protein kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
US-7166597-B2 Fused pyrazole derivatives being protein kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
EP-1311507-B1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LTD (GB) 2006-03-01 EP disclosed
US-20040053942-A1 Fused pyrazole derivatives bieng protein kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053942-A1 Fused pyrazole derivatives bieng protein kinase inhibitors RAF1, SBK3, MAP3K3 MAPK9 65/4885MAPK8 92/4885CSNK1D 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.